



## PATENT <u>IN THE UNITED STATES PATENT AND TRADEMARK OFFICE</u>

Atty Docket No. A01496A TDR/bk

In re application of: James Charles Bohling et al.

Serial No.: 10/786,532

Group Art Unit: 1713

Confirmation No: 2731

Filed:

February 25, 2004

Examiner: Not yet assigned

METHOD OF MANUFACTURING POLYPEPTIDES INCLUDING T-20 For:

AND T-1249 AT COMMERCIAL SCALE, AND POLYPEPTIDE

COMPOSITIONS RELATED THERETO

MAIL STOP AMENDMENT Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with applicant(s)' duty of disclosure under 37 C.F.R. § 1.56(a) and pursuant to 37 C.F.R. § 1.97 - 1.98, Applicant(s) submit(s) herewith copies of the documents listed on the enclosed Form, PTO-1449 "List of Art Cited by Applicant." Inclusion of a document in this Information Disclosure Statement is not intended to constitute an admission that any document so disclosed is "prior art" with respect to the present invention unless specifically so stated herein.

The filing of this Information Disclosure Statement shall not be construed to mean that a search has been made, or that no other material information, as defined in 37 C.F.R. § 1.56(a) exists.

The Examiner may find the enclosed documents relevant to the invention of the present application.

In accordance with 37 CFR §1.98(a)(2), a copy of each item listed on the enclosed Form, PTO-1449, is included herewith except that no copies of the U.S. patent applications are included pursuant to 37 CFR §1.98(a)(2)(iii). Except where noted, each of the items listed are provided in the English language.

#### CERTIFICATION

Check one of the following two paragraphs

- [X] The additional references cited herewith <u>were</u> cited in a communication from a non-US patent office regarding a non-US counterpart application not more than 3 months prior to the filing of this statement, or
- [] The additional references <u>were not</u> cited in such a communication and were not known to any individual having a duty of disclosure more than 3 months prior to the filing of this statement.

Respectfully submitted,

Kenth and

Kenneth Crimaldi Attorney for Applicant(s) Registration No. 40,968

Telephone No.: (215) 592-2423

Rohm and Haas Company 100 Independence Mall West Philadelphia, PA 19106-2399 August 23, 2004



# PATENT IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Docket No. A01496A TDR:bk

In re application of: James Charles Bohling et al.

Serial No.: 10/786,532

Group Art Unit: 1713

Confirmation No. 2731

Filed: February 25, 2004

Examiner: NYA

For: METHOD OF MANUFACTURING POLYPEPTIDES INCLUDING T-20

AND T-1249 AT COMMERCIAL SCALE, AND POLYPEPTIDE

COMPOSITIONS RELATED THERETO

MAIL STOP AMENDMENT Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

### CERTIFICATE OF MAILING

Sir:

I hereby certify that the following correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to MAIL STOP AMENDMENT Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450 on the date indicated next to my signature below:

Supplemental Information Disclosure Statement
List of Art Cited by Applicant
Copies of Cited Art
Return Reciept Postcard

Date Date

Signature



### LIST OF ART CITED BY APPLICANT

(Use several sheets if necessary)

	Sheet 1 of 1
Atty Docket No.	Serial No.
A01496A	10/786,532
Applicant	
James Charle	es Bohling et al.
Filing Date	Group 1713
February 25, 2004	January III II

**U.S. Patent Documents EXAMINER** DOCUMENT NUMBER FILING DATE IF DATE NAME Class/Subclass INITIALS APPROPRIATE AA 6,469,136B1 10/22/2002 Friedrich Paul Erickson et al. AB 2004063856A1 04/01/2004 AC 2003092847A1 05/15/2003 AD AE AF AG AH ΑI AJ AK **FOREIGN PATENT DOCUMENTS** DOCUMENT NUMBER DATE COUNTRY Class/Subclass Translation Yes/No DE4306839A 08/08/1994 DE JP08217794 08/27/1996 JP abstract OTHER ART (Including Author, Title, Date, Pertinent Patents, etc.) Sunil Rana et al, Influence of Resin Cross-Linking on Solid-Phase Chemistry; J. Comb. AR Chem. 2001, 3, pp. 9-15 AS AT **Date Considered** Examiner

<sup>\*</sup>EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.